Glenmark
A new way for a new world

July 2, 2013

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,

We are enclosing herewith a press release informing "**Glenmark Generics receives final ANDA approval for Rizatriptan Benzoate Orally Disintegrating Tablets**" for your information and record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Sanjay Kumar Chowdhary
Company Secretary &Compliance Officer

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)

Encl: As above

Glenmark Generics Ltd.

Press Release

For Immediate Release

Glenmark Generics receives final ANDA approval for Rizatriptan Benzoate Orally Disintegrating Tablets

July 2, 2013: Glenmark Generics Inc, USA, the United States subsidiary of Glenmark Generics Limited, announced today that the United States Food and Drug Administration (U.S. FDA) has granted final approval for Rizatriptan Benzoate Orally Disintegrating Tablets, its generic version of Merck's Maxalt MLT® Tablets. The company will commence shipping immediately.

The approval is for the 5 mg and 10 mg of Rizatriptan ODT. According to IMS Health for the 12 month period ending March 2013, Rizatriptan ODT achieved sales of USD 263 million.

Glenmark's current portfolio consists of 87 products authorized for distribution in the U.S.

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India Tel: [+91 22] 40189919/984
Email: corpcomm@glenmarkpharma.com